Literature DB >> 18061687

Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection.

Nancy M Cladel1, Jiafen Hu, Karla Balogh, Andres Mejia, Neil D Christensen.   

Abstract

The cottontail rabbit papillomavirus (CRPV)/rabbit model has proved useful for the investigation of prophylactic and therapeutic vaccines and for the study of the pathogenesis of papillomavirus infection. It is currently the only animal model in which the entire viral program can be recapitulated, including progression to cancer. CRPV DNA is infectious in domestic rabbits and therefore mutants can be studied without the need to generate corresponding viruses. Although the CRPV animal model is used widely in various laboratories, no optimized or standardized method is used for creating CRPV viral and especially DNA infections. These different methods have made it difficult for investigators to compare results from laboratory to laboratory. A simple and highly efficient method is reported here; it has been refined based on previous methodology for the production of CRPV infections from both virus and plasmid DNA. This method can be adapted easily by other investigators in the field. The resulting standardization will aid in the evaluation of data from different laboratories.

Entities:  

Mesh:

Year:  2007        PMID: 18061687      PMCID: PMC2278115          DOI: 10.1016/j.jviromet.2007.10.005

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  18 in total

1.  Use of a rapid, efficient inoculation method to induce papillomas by cottontail rabbit papillomavirus DNA shows that the E7 gene is required.

Authors:  J L Brandsma; Z H Yang; S W Barthold; E A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection.

Authors:  R Han; C A Reed; N M Cladel; N D Christensen
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

3.  Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas.

Authors:  Jiafen Hu; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas.

Authors:  N D Christensen; M D Pickel; L R Budgeon; J W Kreider
Journal:  Antiviral Res       Date:  2000-11       Impact factor: 5.970

5.  The cottontail rabbit papillomavirus model of high-risk HPV-induced disease.

Authors:  Janet L Brandsma
Journal:  Methods Mol Med       Date:  2005

6.  Impact of genetic changes to the CRPV genome and their application to the study of pathogenesis in vivo.

Authors:  Jiafen Hu; Nancy M Cladel; Karla Balogh; Lynn Budgeon; Neil D Christensen
Journal:  Virology       Date:  2006-10-04       Impact factor: 3.616

7.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Authors:  Y L Lin; L A Borenstein; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.

Authors:  Jiafen Hu; Ricai Han; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.

Authors:  N D Christensen; C A Reed; N M Cladel; R Han; J W Kreider
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  High efficiency induction of papillomas in vivo using recombinant cottontail rabbit papillomavirus DNA.

Authors:  J W Kreider; N M Cladel; S D Patrick; P A Welsh; S L DiAngelo; J M Bower; N D Christensen
Journal:  J Virol Methods       Date:  1995-10       Impact factor: 2.014

View more
  32 in total

1.  Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Nancy Cladel; Karla Balogh; Neil Christensen
Journal:  Vaccine       Date:  2010-03-21       Impact factor: 3.641

2.  Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 DNA and virus.

Authors:  Nancy M Cladel; Lynn R Budgeon; Timothy K Cooper; Karla K Balogh; Jiafen Hu; Neil D Christensen
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

3.  BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Authors:  Mary A Morse; Karla K Balogh; Sarah A Brendle; Colin A Campbell; Mao X Chen; Rebecca C Furze; Isobel L Harada; Ian D Holyer; Umesh Kumar; Kevin Lee; Rab K Prinjha; Martin Rüdiger; Jonathan T Seal; Simon Taylor; Jason Witherington; Neil D Christensen
Journal:  Antiviral Res       Date:  2018-04-11       Impact factor: 5.970

4.  Synonymous codon changes in the oncogenes of the cottontail rabbit papillomavirus lead to increased oncogenicity and immunogenicity of the virus.

Authors:  Nancy M Cladel; Lynn R Budgeon; Jiafen Hu; Karla K Balogh; Neil D Christensen
Journal:  Virology       Date:  2013-02-20       Impact factor: 3.616

5.  Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.

Authors:  Jiafen Hu; Todd D Schell; Xuwen Peng; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Vaccines Vaccin       Date:  2010-08-20

6.  Mouse papillomavirus infections spread to cutaneous sites with progression to malignancy.

Authors:  Nancy M Cladel; Lynn R Budgeon; Timothy K Cooper; Karla K Balogh; Neil D Christensen; Roland Myers; Vladimir Majerciak; Deanna Gotte; Zhi-Ming Zheng; Jiafen Hu
Journal:  J Gen Virol       Date:  2017-10       Impact factor: 3.891

7.  Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model.

Authors:  Jiafen Hu; Lynn R Budgeon; Nancy M Cladel; Karla Balogh; Roland Myers; Timothy K Cooper; Neil D Christensen
Journal:  J Gen Virol       Date:  2015-12       Impact factor: 3.891

8.  Development of an in vivo infection model to study Mouse papillomavirus-1 (MmuPV1).

Authors:  Aayushi Uberoi; Satoshi Yoshida; Paul F Lambert
Journal:  J Virol Methods       Date:  2017-12-15       Impact factor: 2.014

9.  Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Authors:  Subhashini Jagu; Balusubramanyam Karanam; Joshua W Wang; Hatem Zayed; Margit Weghofer; Sarah A Brendle; Karla K Balogh; Kerstin Pino Tossi; Richard B S Roden; Neil D Christensen
Journal:  Vaccine       Date:  2015-09-15       Impact factor: 3.641

10.  The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.

Authors:  Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.